2-硝基-2-苯基乙腈 | 25059-43-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-硝基-2-苯基乙腈
• 英文名称: nitro-phenyl-acetonitrile
• 英文别名: (+/-)-Nitro-phenyl-essigsaeure-nitril；α-Nitro-phenylacetonitril；Phenylcyanonitromethan；Phenylcyannitromethan；α-nitro-benzeneacetonitrile；α-Nitro-benzylcyanid；2-Nitro-2-phenylacetonitrile
• CAS: 25059-43-2
• 化学式: C₈H₆N₂O₂
• 分子量: 162.148
• InChiKey: DBMPHBQSQZZRDP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  69.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-硝基-2-苯基乙腈 在 铜 作用下， 以 苯 为溶剂， 反应 10.0h， 以97%的产率得到苯甲酰腈
  参考文献：
  名称：

  Boyer, Joseph H.; Manimaran, Thanikavelu, Journal of the Chemical Society. Perkin transactions I, 1989, p. 1381 - 1385

  摘要：

  DOI：
• 作为产物：
  描述：

  对硝基甲苯 、 (O-benzoyl-aci-nitro)-phenyl-acetonitrile 生成 2-硝基-2-苯基乙腈
  参考文献：
  名称：

  SALTS OF NITRO COMPOUNDS. I. PREPARATION, ALKYLATION AND ACYLATION OF SALTS OF PHENYLNITROACETONITRILE

  摘要：

  DOI：

  10.1021/jo01225a006

文献信息

• Pyrimidine derivatives as ghrelin receptor modulators
  申请人：Kosogof Christi

  公开号：US20050070712A1

  公开（公告）日：2005-03-31

  The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by ghrelin including anorexia, cancer cachexia, eating disorders, age-related decline in body composition, weight gain, obesity, and diabetes mellitus.

  本发明涉及式(I)的化合物，或者其治疗上适宜的盐或前药，该化合物的制备、含有该化合物的组合物以及在预防或治疗由生长激素释放素调节的疾病中使用该化合物，包括厌食症、癌症恶病质、进食障碍、与年龄相关的身体组成下降、体重增加、肥胖和糖尿病。
• REDUCED COENZYME Q10 DERIVATIVE AND METHOD FOR PRODUCTION THEREOF
  申请人：KANEKA CORPORATION

  公开号：US20150307440A1

  公开（公告）日：2015-10-29

  A reduced coenzyme Q 10 derivative represented by formula (1), wherein R 1 and R 2 are each independently H or an alkoxycarbonyl group represented by formula (2), and at least one of them is an alkoxycarbonyl group represented by the formula (2); in the formula (2), R 3 is an optionally substituted linear, branched, or cyclic alkyl group having 1 to 20 carbon atoms, an optionally substituted aryl group having 6 to 20 carbon atoms, or an optionally substituted heteroaryl group having 4 to 20 carbon atoms, and when R 3 is a group substituted with polyethylene glycol, the molecular weight of the polyethylene glycol is not more than 300.

  公式（1）所代表的一种还原辅酶Q10衍生物，其中R1和R2分别独立地为H或由公式（2）表示的烷氧羰基团，且它们中至少有一个是由公式（2）表示的烷氧羰基团；在公式（2）中，R3是一个可选择地取代的线性、支链或环烷基基团，其含有1至20个碳原子，一个可选择地取代的含有6至20个碳原子的芳基基团，或一个可选择地取代的含有4至20个碳原子的杂芳基团，当R3是一个取代了聚乙二醇的基团时，聚乙二醇的分子量不超过300。
• Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists
  申请人：Kosogof Christi

  公开号：US20050171131A1

  公开（公告）日：2005-08-04

  The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the action of ghrelin receptor, including Prader-Willi syndrome, eating disorder, weight gain, weight-loss maintainance following diet and exercise, obesity, and disorders associated with obesity such as noninsulin dependent diabetes mellitus.

  本发明涉及式(I)的化合物，或其治疗上适用的盐或前药，所述化合物的制备，含有所述化合物的组合物以及在预防或治疗由胃泌素受体调节的疾病中使用所述化合物，包括普拉德-威利综合征、进食障碍、体重增加、饮食和锻炼后体重减轻维持、肥胖，以及与肥胖相关的疾病，如非胰岛素依赖型糖尿病。
• STABILIZATION METHOD OF REDUCED COENZYME Q10
  申请人：UEDA Takahiro

  公开号：US20070258966A1

  公开（公告）日：2007-11-08

  The present invention provides a method for stabilizing reduced coenzyme Q 10 , which is useful as a food, nutritional product, nutritional supplement, animal drug, drink, feed, cosmetic, pharmaceutical product, therapeutic drug, prophylactic drug and the like. The present invention also provides a method of producing a reduced coenzyme Q 10 -containing composition which includes the co-presence of reduced coenzyme Q 10 and reduced coenzyme Q 9 and/or reduced coenzyme Q 11 .

  本发明提供了一种稳定还原型辅酶Q10的方法，可用作食品、营养产品、营养补充剂、动物药品、饮料、饲料、化妆品、药用产品、治疗药物、预防药物等。本发明还提供了一种生产含有还原型辅酶Q10的组合物的方法，其中包括还原型辅酶Q10和还原型辅酶Q9和/或还原型辅酶Q11的共存。
• Novel Biccyclic Compounds As GATA Modulators
  申请人：De Dibyendu

  公开号：US20100144731A1

  公开（公告）日：2010-06-10

  Novel bicyclic compounds, stereoisomers, and/or pharmaceutically acceptable salts of the novel bicyclic compounds, and/or pharmaceutically acceptable salts of the stereoisomers of the novel bicyclic compounds are provided. Additionally, methods of forming novel bicyclic compounds, stereoisomers, and/or pharmaceutically acceptable salts of the novel bicyclic compounds, and/or pharmaceutically acceptable salts of the stereoisomers of the novel bicyclic compounds are provided.

  提供了新型双环化合物、立体异构体和/或新型双环化合物的药用可接受盐，以及新型双环化合物的立体异构体的药用可接受盐。此外，还提供了形成新型双环化合物、立体异构体和/或新型双环化合物的药用可接受盐，以及新型双环化合物的立体异构体的药用可接受盐的方法。